Psoriasis | Access & Reimbursement | US | 2022

Janssen’s interleukin (IL)-12/23 inhibitor Stelara, AbbVie’s tumor necrosis factor-alpha (TNF-α) inhibitor Humira, and Novartis’s IL-17A inhibitor Cosentyx lead the U.S. psoriasis biologics market, but the approval of novel, more-effective therapies has started changing the landscape as newer biologics gain greater acceptance from treating physicians. Eli Lilly’s IL-17 inhibitor Taltz and Amgen’s oral PDE-4 inhibitor Otezla have successfully carved out space in the treatment algorithm. More-effective biologics—AbbVie’s Skyrizi and Janssen’s Tremfya—and emerging therapies in the late-phase pipeline are threatening the dominance of earlier-to-market biologics. Given the recent entry of infliximab biosimilars, along with the development of another IL-17 A/F dual inhibitor, an oral TYK2 inhibitor, and two novel topical therapies, marketers of psoriasis therapies must learn how to navigate this increasingly competitive market.

QUESTIONS ANSWERED

• Among commercially insured psoriasis patients, what percentage receive newer biological agents, and which biologics / Otezla do physicians perceive to perform the best on specific clinical and market access factors?
• How do payers cover biosimilar versions of infliximab (Pfizer’s Inflectra, Merck’s Renflexis, and Amgen’s Avsola), and how do physicians expect to prescribe these biosimilars?
• What are physician perceptions of emerging therapies such as bimekizumab, Remsima (SC), deucravacitinib, and emerging nonsteroidal topical agents with novel mechanisms of action? How do payers anticipate covering these agents?
• For psoriasis drugs with similar efficacy and safety, what economic factors most influence favorable coverage in MCOs’ largest fully insured plans?

PRODUCT DESCRIPTION

U.S. Access & Reimbursement provides integrated brand- and disease-level insight on reimbursement dynamics and the impact of U.S. payer policy on physician prescribing behavior in the market access environment, including up-to-date analysis of drug coverage and restriction policies and payer and prescriber perspectives on key marketed drugs and receptivity to emerging therapies.

Key drugs: Humira, Enbrel, Remicade, Inflectra, Renflexis, Avsola, Cimzia, Stelara, Otezla, Cosentyx, Taltz, Siliq, Tremfya, Ilumya, Skyrizi, Remsima (SC), bimekizumab, deucravacitinib, roflumilast (topical), tapinarof

Key companies: AbbVie, Amgen, Arcutis, Bristol-Myers Squibb, Dermavant, Eli Lilly, Janssen, Merck, Pfizer, Novartis, UCB.